The SAFE CATTLE Act requires the U.S. Departments of Agriculture and Interior to coordinate federal efforts to prevent, monitor, and eradicate New World screwworm - a pest that attacks livestock and wildlife - across federal lands managed by agencies like the National Park Service and Fish and Wildlife Service. It mandates joint surveillance protocols, outbreak response plans with state officials, and science-based strategies to protect livestock industries and food supply chains. The bill also requires annual reports to Congress detailing interagency progress, outbreak responses, and recommendations for improving pest control until screwworm is contained south of Panama. This legislation directly affects federal land managers, livestock producers, and the broader agricultural economy by establishing a formal federal framework for addressing this specific animal health threat.
The Whale CHARTS Act of 2026 establishes a program to protect migratory whales and other large cetaceans through improved mapping, monitoring, and mitigation measures. It requires the creation of detailed, high-resolution maps of whale habitats, including calving grounds and migration routes, which will be integrated into vessel navigation systems to prevent collisions. The bill authorizes $8 million annually through 2030 for mapping, surveys, and a $10 million grant program to fund new detection technologies that reduce harmful interactions between whales and ocean users. It also mandates regular reporting to Congress on the program's effectiveness and progress in filling knowledge gaps about whale habitats.
HR 6529, the Protecting Families from AI Data Center Energy Costs Act, mandates the Federal Energy Regulatory Commission (FERC) to hold a technical conference within 90 days of enactment. The conference will include AI data centers, utilities, and ratepayer advocates to develop strategies protecting residential and small commercial customers from rising energy costs caused by large energy users. FERC must then submit a report with recommendations to Congress within 180 days. This procedural bill directly affects households and small businesses facing potential rate increases due to AI data center energy demands.
HR 6213, the Heat Workforce Standards Act of 2025, prohibits the U.S. Department of Labor from finalizing, implementing, or enforcing OSHA's proposed "Heat Injury and Illness Prevention" standard (published August 30, 2024). This bill directly blocks the specific regulatory proposal targeting heat safety in both outdoor and indoor work settings. It does not create new requirements or affect workers; it solely prevents the implementation of the existing OSHA proposal. The bill is procedural, focusing on halting a regulatory action rather than establishing new policy.
The NIH IMPROVE Act (HR 6238) establishes a new NIH research initiative focused on improving maternal health outcomes in the U.S. It directly affects pregnant and postpartum women, particularly those in communities experiencing health disparities linked to higher maternal mortality and severe maternal morbidity. The bill authorizes $73.4 million annually (2026-2031) for NIH to fund research targeting preventable causes of maternal deaths, reduce health disparities, and evaluate community-based interventions. Key provisions require NIH to advance evidence-based solutions through grants and studies on biological, behavioral, and regional factors affecting maternal health before, during, and after pregnancy.
HR 4986, the Parents Opt-in Protection Act, amends federal law to require written permission before schools administer certain student surveys or evaluations. It directly affects students (especially minors) and their parents, requiring schools to obtain prior written consent from the student (if an adult or emancipated minor) or the parent (for minors) for each specific survey. The bill clarifies that schools cannot force participation without this written consent for surveys related to sensitive topics like health or behavior. This change updates existing consent rules from verbal permission to a written requirement for targeted school assessments.
This bill reauthorizes federal programs focused on preventing and responding to tick-borne diseases through 2026-2030, extending existing efforts beyond their previous expiration. It updates the National Strategy for Vector-Borne Diseases to emphasize identifying, reporting, preventing, and responding to these illnesses. The bill modifies two sections of the Public Health Service Act to continue funding for health departments working on vector-borne disease control. It directly affects public health programs and state/local health departments managing tick-borne disease prevention and response.
The AADAPT Act reauthorizes and expands Project ECHO grants to improve Alzheimer’s and dementia care through technology-enabled training. It specifically funds grants for healthcare providers in rural, frontier, or medically underserved areas to enhance early diagnosis, quality care, and provider retention for dementia patients. The bill authorizes $1 million annually (2027-2032) for these dementia-focused training programs, requiring funds to supplement - not replace - existing resources. This directly supports primary care providers licensed to serve underserved communities, using collaborative online learning to address care gaps.
HR 2821, the FDA Modernization Act 3.0, requires the FDA to update regulatory language within one year of enactment. It directs the agency to replace all references to "animal tests" with "nonclinical tests" in 22 specific sections of the Code of Federal Regulations related to drug development and approval processes. The bill also adds a definition for "nonclinical test" into relevant FDA regulations to align with prior legislative changes. This update applies directly to pharmaceutical manufacturers and FDA reviewers who follow these regulatory guidelines during drug development. The changes aim to modernize terminology without altering current testing requirements.
HR 2001 increases annual funding for a grant program supporting dental workforce development from $13.9 million to $15 million, extending the program through fiscal years 2026-2030 (previously 2019-2023) under the Public Health Service Act. The bill modifies existing funding levels to maintain support for addressing dental workforce shortages, with funds remaining available until expended. This change directly affects the operation of the grant program and its ability to fund dental workforce initiatives.
HR 2004, titled "Tyler’s Law," requires the Secretary of Health and Human Services to study how often hospital emergency departments test for fentanyl during overdose cases (beyond standard drug tests), including associated costs, patient benefits/risks, and impacts on privacy and patient-physician relationships. The study must be completed within one year of the bill's enactment. Based on the study results, the Secretary must issue guidance within six months on whether emergency departments should routinely test for fentanyl, how to inform clinicians about test contents, and how such testing may affect future overdose risks and health outcomes. This bill directly affects hospital emergency departments and patients experiencing overdoses by shaping future testing protocols.
HR 1266, the Combating Illicit Xylazine Act, adds xylazine - a veterinary sedative increasingly found in illicit drug mixtures - to Schedule III of the Controlled Substances Act, regulating its use and trafficking. It directly affects veterinarians, animal owners, and manufacturers by allowing xylazine to be legally dispensed for animal use under specific veterinary prescriptions, while prohibiting non-veterinary human use. The bill includes transition periods (60 days for practitioners, 1 year for labeling) to ease compliance for manufacturers and practitioners, and requires the DEA and FDA to expedite necessary applications. It also mandates two congressional reports on xylazine's illicit use and trafficking patterns, and directs the Sentencing Commission to review penalties for offenses involving xylazine.
